The feasibility of obtaining oncotype DX breast recurrence score® results from metastatic sites of patients with hormone receptor positive metastatic breast cancer

被引：0
|
作者：
Gemmill, Julie Anne L. [1 ]
Thompson, Patricia [1 ]
Batiste, Rebecca [1 ]
Vacchi-Suzzi, Caterina [1 ]
Preece, Christina [1 ]
Cohen, Jules [1 ]
Baer, Lea [1 ]
Mies, Carolyn [2 ]
Turner, Michelle [2 ]
Russell, Christy A. [2 ]
Stopeck, Alison [1 ]
机构：
[1] SUNY Stony Brook, Med Ctr, Stony Brook, NY 11794 USA
[2] Genom Hlth Inc, Redwood City, CA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS5-37
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical outcomes in breast cancer (BC) patients (pts) with intermediate Oncotype DX Recurrence Score (RS) results
    Leitzin, L.
    Sikorsky, N.
    Popovich-Hadari, N.
    Leviov, M.
    BREAST, 2017, 32 : S99 - S99
  • [32] Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results
    Kamaljeet Singh
    Xin He
    Elizabeth T. Kalife
    Shahrzad Ehdaivand
    Yihong Wang
    C. James Sung
    Breast Cancer Research and Treatment, 2018, 168 : 29 - 34
  • [33] Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas
    Emmadi, Rajyasree
    Canestrari, Emanuele
    Arbieva, Zarema H.
    Mu, Wenbo
    Dai, Yang
    Frasor, Jonna
    Wiley, Elizabeth
    PLOS ONE, 2015, 10 (12):
  • [34] The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists
    Joh, Jennifer E.
    Esposito, Nicole N.
    Kiluk, John V.
    Laronga, Christine
    Lee, M. Catherine
    Loftus, Loretta
    Soliman, Hatem
    Boughey, Judy C.
    Reynolds, Carol
    Lawton, Thomas J.
    Acs, Peter I.
    Gordan, Lucio
    Acs, Geza
    ONCOLOGIST, 2011, 16 (11): : 1520 - 1526
  • [35] Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
    Lux, Michael Patrick
    Minartz, Christof
    Mueller-Huesmann, Harald
    Sandor, Marianar Felicia
    Radeck-Knorre, Sabine
    Neubauer, Aljoscha Steffen
    BREAST CARE, 2024, 19 (01) : 27 - 33
  • [36] Prognostic impact of HER2-low expression according to the oncotype Dx recurrence score in hormone receptor-positive early breast cancer
    Mutai, R.
    Barkan, T.
    Moore, A.
    Sarfaty, M.
    Stemmer, S.
    Shohat, T.
    Yerushlami, R.
    Goldvaser, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S424 - S424
  • [37] Prediction of Oncotype DX Recurrence Score Based on Systematic Evaluation of Ki-67 Scores in Hormone Receptor- Positive Early Breast Cancer
    Kim, Ji Min
    Cho, Eun Yoon
    JOURNAL OF BREAST CANCER, 2024, 27 (03) : 201 - 214
  • [38] Everolimus in metastatic hormone-receptor positive Breast Cancer
    Richter-Ehrenstein, C.
    ONKOLOGE, 2012, 18 (05): : 435 - +
  • [39] Impact of Oncotype DX Recurrence Score on Breast Cancer Prognostic Stage Group
    Breaux, Andrea C.
    Sanders, Mary Ann
    Turner, Bradley M.
    Wu, Xiaoyong
    Rai, Shesh N.
    Riley, Elizabeth C.
    MODERN PATHOLOGY, 2018, 31 : 52 - 52
  • [40] Impact of Oncotype DX Recurrence Score on Adjuvant Chemotherapy Recommendations in Young Patients with Breast Cancer
    Dodman, Keisha G.
    Williams, Austin D.
    De La Cruz, Lucy M.
    Tchou, Julia C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 227 (04) : E6 - E6
12345